Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alnylam Pharmaceuticals's enterprise value is $27,290 Mil.
Alnylam Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,179 Mil. Therefore, Alnylam Pharmaceuticals's EV-to-EBITDA for today is 23.14.
The historical rank and industry rank for Alnylam Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LTS:0HD2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -613.3 Med: -20.68 Max: 276.8
Current: 23.14
During the past 13 years, the highest EV-to-EBITDA of Alnylam Pharmaceuticals was 276.80. The lowest was -613.30. And the median was -20.68.
LTS:0HD2's EV-to-EBITDA is ranked worse than 65.28% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs LTS:0HD2: 23.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alnylam Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Alnylam Pharmaceuticals's share price for today is $215.17.
Alnylam Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs ONC, RVMD, RPRX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's EV-to-EBITDA falls into.
Alnylam Pharmaceuticals's current Enterprise Value is $27,290 Mil.
Alnylam Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,179 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a EV-to-EBITDA of 23.14 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alnylam Pharmaceuticals. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #267 out of 409 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Alnylam Pharmaceuticals' EV-to-EBITDA too high?
Alnylam Pharmaceuticals' current EV-to-EBITDA is 23.14. The Biotechnology industry median EV-to-EBITDA is 12.99. Alnylam Pharmaceuticals' value of 23.14 is 78.1% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #267 out of 409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' EV-to-EBITDA compare to ONC and RVMD?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #267 out of 409 companies for EV-to-EBITDA. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. Alnylam Pharmaceuticals' value of 23.14 is 78.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current EV-to-EBITDA of 23.14 is 78.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alnylam Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current EV-to-EBITDA is 23.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $516.05, compared to a current price of $215.17 — trading 58.3% below its estimated fair value. The current EV-to-EBITDA is 23.14 and 78.1% above the Biotechnology industry median of 12.99. Alnylam Pharmaceuticals' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current EV-to-EBITDA is 23.14 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $215.17 is trading 58.3% below its estimated GF Value™ of $516.05.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
EV-to-EBITDA: 23.14
GF Value™: $516.05 vs. price of $215.17 (58.3% below fair value)
Industry Position: 78.1% above the Biotechnology median (#267 of 409)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
68GF Score
Get the complete analysis for LTS:0HD2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
